A pilot study of first-line chemotherapy with 5-FU and Platinum in advanced and recurrent cancer of the cervix

• Main Authors: Ghaemmaghami F, Behtash N, Yarandi F, Moosavi A, Toogeh Gh.R, Khanafshar N
• Format: Article
• Language: English
• Published: Tehran University of Medical Sciences 2003-06-01
• Series: Acta Medica Iranica
• Subjects: Cervix; Carcinoma; Platinum; 5-FU; Palliation
• Online Access: http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/1050.pdf&manuscript_id=1050

This study was designed to assess the role of first-line chemotherapy with 5-FU and platinum in the treatment of advanced or recurrent cervical cancer, ten patients with advanced or recurrent cancer of the cervix, with no prior chemotherapy were entered in phase II trial, from Oct. 2000 to Nov. 2001. Eight patients were treated with cis-platinum (50 mg/m2 over 60 minutes in first day) followed by 5-FU (1 g/m2 over 24 hours for 4 days) and two patients with impaired renal function were treated with carboplatin (300 mg/m2 over 15 minutes in first day) followed by 5-FU (1 g/m2 over 24 hours for 4 days) every three weeks, until progression of disease or prohibitive toxicity had been observed. Median age was 52 years (range: 28-70 years). Ten patients received a total of 42 cycles of chemotherapy. The mean number of chemotherapy cycles was 4.2 (median 4, range: 3-7). Three patients had partial response (30%, CI, 1.7%-58.5%). Mean response duration was 198 days (range: 122-273 days). Four patients required red blood cell transfusions; three of them had grade II and one of them grade III nausea and vomiting Two had fever and neutropenia (one developed acute renal insufficiency), and there wee no treatment related mortalities. First-line chemotherapy with platinum and 5-FU for advanced recurrent cervical cancer is promising and deserves consideration for large phase III trials.